Arlocabtagene autoleucel
- Generic Name
- Arlocabtagene autoleucel
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3
Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 440
- Registration Number
- NCT06615479
- Locations
- ๐บ๐ธ
Local Institution - 0071, Birmingham, Alabama, United States
๐บ๐ธUCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
๐บ๐ธLocal Institution - 0130, Miami, Florida, United States
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 111
- Registration Number
- NCT06121843
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
๐บ๐ธMayo Clinic in Florida, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Target Recruit Count
- 180
- Registration Number
- NCT04674813
- Locations
- ๐บ๐ธ
Local Institution - 008, Baltimore, Maryland, United States
๐บ๐ธLocal Institution - 009, Duarte, California, United States
๐บ๐ธLocal Institution - 011, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath